The effect of insulin glargine and fish oil supplements on atherosclerosis progression

August 27, 2012

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.

However, while glargine did significantly reduce the secondary outcomes of the study (the annualised rates of change in maximum CIMT for the common carotid artery and for the common carotid plus bifurcation sites), there was no differences in either the primary or secondary outcomes between the omega-3 polyunsaturated and placebo groups.

"Our study demonstrates that in high-risk people with established cardiovascular disease or with plus type 2 diabetes or pre-diabetes, insulin glargine modestly retards the progression of atherosclerosis," said first investigator Professor Eva Lonn, Professor of Medicine and Population Health Research Scientist at McMaster University, Hamilton, Ontario, Canada.

As background to the trial, known as the Glucose Reduction and Atherosclerosis Continuing Evaluation Study (GRACE) study, Professor Lonn explained that the effects of treatment with insulin titrated to normalise fasting and with omega-3 polyunsaturated fatty acid supplements () on atherosclerosis progression in people with type 2 diabetes or pre-diabetes are unknown.

The GRACE study assessed the effects of insulin glargine and omega-3 by performing yearly high-resolution carotid ultrasound examinations for five years and detailed of CIMT. Patients were recruited from 32 centers in seven countries. At baseline patients' mean age was 63 years, over 50% had a history of prior heart attack, stroke or revascularisation, 80% had hypertension, 60% abnormal cholesterol and 10% were current smokers. About 90% had type 2 diabetes and 10% had pre-diabetes.

Most patients were receiving several therapies aimed at reducing their risk for atherosclerosis and its complications. Use of these drugs increased over the duration of the study, so that at study end 52% were on statins, 75% on ACE inhibitors or ARBs, 55% on beta-blockers and 70% on aspirin. Patients received open label insulin glargine targeting normal glucose levels or standard glycemic care, and double-blind therapy with a 1 gram per day supplement of or placebo. Median follow-up was five years.

Insulin glargine significantly lowered fasting plasma glucose, glycated hemoglobin and triglyceride levels and provided overall "excellent" glycemic control, said Professor Lonn, while omega-3 fatty acid supplements had no significant effect on glycemia or on lipid levels. Both interventions were safe.

Compared with the standard glycemic care, insulin glargine reduced the primary CIMT outcome, but the difference was not statistically significant (difference = 0.0030 ±0.0021 mm/year; p=0.145) and significantly reduced the secondary outcomes (difference = 0.0033 ±0.0017 mm/year; p=0.049 and 0.0045 ±0.0021 mm/year; p=0.032). There was no beneficial effect of omega-3 polyunsaturated fatty acid supplements on either outcome.

"These findings support the cardiovascular safety of this intervention," said Professor Lonn, "and suggest that longer term treatment with insulin glargine might prevent cardiovascular events. In the parent ORIGIN trial had a neutral effect on cardiovascular events over 6.2 years. Whether longer-term therapy may result in clinical event reduction remains currently unproven."

"The neutral effect of omega-3 polyunsaturated fatty acid supplements on atherosclerotic vascular disease is also concordant with the neutral effect on clinical cardiovascular effects in the parent ORIGIN trial. Some, but not all, previous studies reported beneficial effects of omega-3 polyunsaturated fatty acid supplements in cardiovascular event prevention and several large ongoing trials are still evaluating this question. Our study does not address the current recommendations to consume more fish, which may have health benefits not conferred by fish oil supplements."

Explore further: Study debunks belief insulin puts people with diabetes at risk of heart disease

Related Stories

Study debunks belief insulin puts people with diabetes at risk of heart disease

June 11, 2012
Researchers at McMaster University have discovered that long-term insulin use does not harm people with diabetes or pre-diabetes or put them at risk of heart attacks, strokes or cancer.

Fish oil won't save diabetics' hearts, research suggests

June 11, 2012
(HealthDay) -- People with type 2 diabetes who take omega-3 fatty acid supplements are neither helping nor harming their heart, a new study finds.

Omega-3 supplements no help against repeat heart trouble: review

April 9, 2012
(HealthDay) -- Taking omega-3 fatty acid supplements won't protect against repeat heart attacks, strokes or other cardiovascular problems, a new analysis indicates.

Vitamin B and omega-3 supplementation and cancer: new data

February 17, 2012
Researchers from the Nutritional Epidemiology Joint Research Unit have just published a study showing that, in men with a previous history of cardiovascular pathologies, supplementation with B vitamins and omega-3 polyunsaturated ...

Omega-3 fatty acids not associated with beneficial effects in multiple sclerosis: study

April 23, 2012
Omega-3 fatty acid supplements were not associated with beneficial effects on disease activity in patients with relapsing-remitting multiple sclerosis, according to a report of a randomized controlled trial published Online ...

Recommended for you

New molecule may hold the key to triggering the regeneration and repair of damaged heart cells

August 21, 2017
New research has discovered a potential means to trigger damaged heart cells to self-heal. The discovery could lead to groundbreaking forms of treatment for heart diseases. For the first time, researchers have identified ...

Researchers investigate the potential of spider silk protein for engineering artificial heart

August 18, 2017
Ever more people are suffering from cardiac insufficiency, despite significant advances in preventing and minimising damage to the heart. The main cause of reduced cardiac functionality lies in the irreversible loss of cardiac ...

Lasers used to detect risk of heart attack and stroke

August 18, 2017
Patients at risk of heart attacks and strokes may be spotted earlier thanks to a diagnosis tool that uses near-infrared light to identify high-risk arterial plaques, according to research carried out at WMG, University of ...

Cholesterol crystals are sure sign a heart attack may loom

August 17, 2017
A new Michigan State University study on 240 emergency room patients shows just how much of a role a person's cholesterol plays, when in a crystallized state, during a heart attack.

How Gata4 helps mend a broken heart

August 15, 2017
During a heart attack, blood stops flowing into the heart; starved for oxygen, part of the heart muscle dies. The heart muscle does not regenerate; instead it replaces dead tissue with scars made of cells called fibroblasts ...

Injectable tissue patch could help repair damaged organs

August 14, 2017
A team of U of T Engineering researchers is mending broken hearts with an expanding tissue bandage a little smaller than a postage stamp.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.